Review
Immunology
Justin Loke, Richard Buka, Charles Craddock
Summary: While most AML patients achieve complete remission with intensive chemotherapy, many face a risk of relapse if treated with chemotherapy alone. Allogeneic stem cell transplant has become a key treatment strategy for AML patients, especially for those in first complete remission and advanced stages. Despite a decrease in transplant-related mortality, there remains a need to address the risk of disease relapse.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Cristina Tecchio, Anna Russignan, Mauro Krampera
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) benefits adult ALL patients, but those with MRD may require interventions with side effects. The significance of MFC in ALL treatment is widely recognized, but there is limited data on MRD monitoring in allo-HSCT settings. This article aims to summarize and discuss the role of MFC detection of MRD in adult ALL patients undergoing allo-HSCT, including sensitivity, timing, and relation to other MRD assessment techniques.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Mahmoud R. Gaballa, Pinaki Banerjee, Denai R. Milton, Xianli Jiang, Christina Ganesh, Sajad Khazal, Vandana Nandivada, Sanjida Islam, Mecit Kaplan, May Daher, Rafet Basar, Amin Alousi, Rohtesh Mehta, Gheath Alatrash, Issa Khouri, Betul Oran, David Marin, Uday Popat, Amanda Olson, Priti Tewari, Nitin Jain, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Ken Chen, Richard Champlin, Elizabeth Shpall, Katayoun Rezvani, Partow Kebriaei
Summary: This study examined the feasibility and efficacy of blinatumomab in high-risk acute lymphoblastic leukemia patients after allogeneic hematopoietic cell transplantation. The results showed that blinatumomab treatment was feasible and effective in reducing the risk of relapse, with specific T-cell profiles associated with treatment response.
Article
Immunology
Edyta Heropolitanska-Pliszka, Barbara Piatosa, Anna Szmydki-Baran, Karolina Kuczborska, Karolina Miarka-Walczyk, Agata Pastorczak, Wojciech Mlynarski, Lukasz Sedek, Tomasz Szczepanski, Marek Ussowicz
Summary: This study reports a successful bone marrow transplantation in a carrier of a novel GATA2 pathogenic variant who had previously been treated for B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The study highlights the importance of genetic counseling and family screening prior to selecting related hematopoietic stem cell transplantation (HSCT) donors.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Shuang Fan, Tian-Zhong Pan, Li-Ping Dou, Yan-Min Zhao, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Xiao-Jun Huang, Xiao-Dong Mo
Summary: The study aimed to assess the efficacy of preemptive interferon-alpha (IFN-alpha) treatment in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a real-world setting. The results showed that preemptive IFN-alpha treatment can eliminate measurable residual disease (MRD) in AML patients and improve leukemia-free survival.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Patrizia Chiusolo, Elisabetta Metafuni, Gessica Minnella, Sabrina Giammarco, Silvia Bellesi, Monica Rossi, Federica Sora, Maria Assunta Limongiello, Filippo Frioni, Nicola Piccirillo, Maria Bianchi, Caterina Giovanna Valentini, Luciana Teofili, Simona Sica, Andrea Bacigalupo
Summary: The aim of this study was to evaluate the role of WT1 expression after allogeneic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML). The results showed that WT1 expression at day 60 is a significant predictor of relapse, particularly when tested on CD34+ selected bone marrow cells.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jun Kong, Meng-Ge Gao, Ya-Zhen Qin, Yu Wang, Chen-Hua Yan, Yu-Qian Sun, Ying-Jun Chang, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Su Zhao
Summary: This study aimed to analyze the dynamic changes of MLL-PTD peri-transplantation and determine the best threshold for predicting relapse after transplantation. The study included 48 patients with MLL-PTD AML or MDS-EB who underwent allo-HSCT. The results showed that MLL-PTD after transplantation can serve as an effective indicator for predicting relapse. The expression level of MLL-PTD >= 1.0% was identified as the optimal cut-off value for predicting hematological relapse after allo-HSCT.
Article
Oncology
Jordi Esteve, Sebastian Giebel, Myriam Labopin, Tomasz Czerw, Depei Wu, Liisa Volin, Gerard Socie, Ibrahim Yakoub-Agha, Johan Maertens, Jan J. Cornelissen, Arnaud Pigneux, Avichai Shimoni, Rainer Schwerdtfeger, Helene Labussiere-Wallet, Nigel Russell, Anton Schattenberg, Patrice Chevallier, Vladimir Koza, Robin Foa, Christoph Schmid, Zinaida Peric, Mohamad Mohty, Arnon Nagler
Summary: This study analyzed the outcomes of patients with t(4;11) BCP-ALL treated with alloHSCT, finding that a negative MRD status pre-transplant was the strongest beneficial factor. Patients with t(4;11) BCP-ALL had inferior outcomes compared to those with NK BCP-ALL when MRD was detectable.
Article
Hematology
Davide Lazzarotto, Ilaria Tanasi, Antonella Vitale, Matteo Piccini, Michelina Dargenio, Fabio Giglio, Fabio Forghieri, Nicola Fracchiolla, Marco Cerrano, Elisabetta Todisco, Cristina Papayannidis, Matteo Leoncin, Marzia Defina, Fabio Guolo, Crescenza Pasciolla, Mario Delia, Patrizia Chiusolo, Antonino Mule, Anna Candoni, Massimiliano Bonifacio, Giovanni Pizzolo, Robin Foa
Summary: Mixed-phenotype acute leukemia (MPAL) is a rare disease, and its treatment is often similar to that of acute lymphoblastic leukemia (ALL). This study found that MPAL patients respond better to an ALL-like induction therapy, and consolidation therapy should include allogeneic stem cell transplantation (AlloSCT) whenever possible. Additionally, achieving minimal residual disease (MRD) negativity should be a primary goal of treatment.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Xiao-Lin Yuan, Ya-Min Tan, Ji-Min Shi, Yan-Min Zhao, Jian Yu, Xiao-Yu Lai, Lu-Xin Yang, He Huang, Yi Luo
Summary: Preemptive low-dose IL2 and preemptive DLI have comparable outcomes for patients with late-onset MRD receiving allo-HSCT, with lower incidence of moderate/severe cGVHD and higher GRFS in the IL2 group. IL2 may be an alternative method for patients who develop LMRD after allo-HSCT, particularly for those who cannot receive preemptive DLI.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Hisashi Ishida, Motohiro Kato, Yuta Kawahara, Sae Ishimaru, Yuho Najima, Shinichi Kako, Maho Sato, Mitsuteru Hiwatari, Maiko Noguchi, Keisuke Kato, Katsuyoshi Koh, Keiko Okada, Fuminori Iwasaki, Ryoji Kobayashi, Shunji Igarashi, Shoji Saito, Yoshiyuki Takahashi, Atsushi Sato, Junji Tanaka, Yoshiko Hashii, Yoshiko Atsuta, Hirotoshi Sakaguchi, Toshihiko Imamura
Summary: This study retrospectively analyzed the outcomes of hematopoietic stem cell transplantation (HSCT) in children and adolescents with T-cell acute lymphoblastic leukemia (T-ALL). The results showed that HSCT at the first complete remission had better survival rates, but once relapse occurred, the prognosis was worse. Higher grades of graft versus host disease were associated with lower overall and leukemia free survival rates. Cord blood transplantation with total-body irradiation-based myeloablative conditioning showed better outcomes compared to other conditioning regimens.
HEMATOLOGICAL ONCOLOGY
(2022)
Article
Immunology
Meng-Zhu Shen, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Su Zhao, Ya-Zhen Qin, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Dong Mo
Summary: The long-term efficacy of preemptive interferon-alpha therapy in acute myeloid leukemia patients following allogeneic hematopoietic stem cell transplantation was assessed. The results showed that preemptive interferon-alpha therapy could clear minimal residual disease persistently, prevent relapse, and improve long-term survival in patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Emily C. Liang, Juliana Craig, Stefan Torelli, Kristen Cunanan, Maria Iglesias, Sally Arai, Matthew J. Frank, Laura Johnston, Robert Lowsky, Everett H. Meyer, David B. Miklos, Robert Negrin, Andrew Rezvani, Parveen Shiraz, Judith Shizuru, Surbhi Sidana, Wen-Kai Weng, Sushma Bharadwaj, Lori Muffly
Summary: This study evaluated the characteristics and outcomes of adult ALL patients undergoing allogeneic HCT over the last decade. The results showed that overall survival after HCT for adult ALL has improved in recent years, partly due to the improved ability to effectively salvage patients relapsing after HCT.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Oncology
Yu Wang, Yu-Juan Xue, Yue-Ping Jia, Ying-Xi Zuo, Ai-Dong Lu, Le-Ping Zhang
Summary: The re-emergence of minimal residual disease (MRD) during treatment for pediatric acute lymphoblastic leukemia (ALL) is associated with an adverse outcome, but transplantation can significantly improve survival and reduce the incidence of relapse in these patients. High white blood cell counts and elevated MRD levels on day 33 are risk factors for MRD re-emergence.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Jia Liu, Zhong-Xing Jiang, Xin-Sheng Xie, Ding-Ming Wan, Wei-Jie Cao, Meng Wang, Zhen-Zhen Liu, Zhen-Kun Dong, Hai-Qiong Wang, Run-Qing Lu, Yin-Yin Zhang, Qian-Qian Cheng, Ji-Xin Fan, Wei Li, Fei He, Rong Guo
Summary: The study suggests that maintenance treatment with low-dose decitabine may help reduce relapse in adult ALL patients after allo-HSCT, especially in T-ALL patients. The occurrence of GVHD is relatively low during treatment, indicating good safety profile.
FRONTIERS IN ONCOLOGY
(2021)
